Eagle Pharmaceuticals, which develops and sells enhanced injectable products, announced terms for its IPO on Tuesday. The Woodcliff Lake, NJ-based company plans to raise $50 million by offering 3.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Eagle Pharmaceuticals would command a fully diluted market value of $216 million.
Eagle Pharmaceuticals, which was founded in 2007 and booked $14 million in sales for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol EGRX. Eagle Pharmaceuticals initially filed confidentially on October 21, 2013. Piper Jaffray and William Blair are the joint bookrunners on the deal.
